Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.